Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 11/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045231 | 0.86 | TGFBR1 (0.46) | TGFBR1CYP2A6RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6727975 | 0.81 | RPS6KA3 (0.69) | RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6732861 | 0.81 | TGFBR1 (0.43) | TGFBR1CYP2A6PTGS2 | |
| SCHEMBL6735985 | 0.80 | CYP2A6 (0.41) | TGFBR1CYP2A6RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6731479 | 0.80 | RPS6KA3 (0.41) | RPS6KA3PTGS2 | |
| SCHEMBL6728690 | 0.80 | RPS6KA3 (0.63) | RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6733560 | 0.80 | RPS6KA3 (0.53) | RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6718301 | 0.80 | TGFBR1 (0.45) | TGFBR1CYP2A6RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6735867 | 0.79 | RPS6KA3 (0.44) | RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL6736797 | 0.79 | SLC22A12 (0.58) | RPS6KA3PTGS2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | TGFBR1 1183/4885CYP2A6 574/4885RPS6KA3 1600/4885 |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | TGFBR1 1183/4885CYP2A6 574/4885RPS6KA3 1600/4885 |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | TGFBR1 1183/4885CYP2A6 574/4885RPS6KA3 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.